Healthcare provider profile · identity verified

Alan M. Pollack, MD

Internal Medicine · PANORAMA CITY, CA · NPI 1477624401

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	545	227
Amlodipine Besylate	Amlodipine Besylate	371	144
Lisinopril	Lisinopril	320	117
Rosuvastatin Calcium	Rosuvastatin Calcium	311	128
Losartan Potassium	Losartan Potassium	308	120
Metformin Hcl	Metformin Hcl	242	97
Metformin Hcl Er	Metformin Hcl	200	81
Jardiance	Empagliflozin	181	61
Levothyroxine Sodium	Levothyroxine Sodium	154	56
Terazosin Hcl	Terazosin Hcl	140	51
Allopurinol	Allopurinol	104	39
Pradaxa	Dabigatran Etexilate Mesylate	104	34
Simvastatin	Simvastatin	102	42
Famotidine	Famotidine	94	39
Glipizide	Glipizide	93	43
Hydrochlorothiazide	Hydrochlorothiazide	93	41
Atenolol	Atenolol	85	40
Finasteride	Finasteride	82	32
Ezetimibe	Ezetimibe	73	28
Omeprazole	Omeprazole	72	30
Tamsulosin Hcl	Tamsulosin Hcl	68	27
Hydralazine Hcl	Hydralazine Hcl	67	22
Gabapentin	Gabapentin	65	31
Ozempic	Semaglutide	63	14
Pioglitazone Hcl	Pioglitazone Hcl	60	24
Alendronate Sodium	Alendronate Sodium	58	28
Metoprolol Tartrate	Metoprolol Tartrate	56	22
Triamcinolone Acetonide	Triamcinolone Acetonide	54	33
Meloxicam	Meloxicam	53	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	50	21
Albuterol Sulfate Hfa	Albuterol Sulfate	42	30
Potassium Chloride	Potassium Chloride	41	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	40	15
Trazodone Hcl	Trazodone Hcl	40	19
Carvedilol	Carvedilol	36	11
Clopidogrel	Clopidogrel Bisulfate	35	12
Sertraline Hcl	Sertraline Hcl	34	16
Spironolactone	Spironolactone	33	11
Furosemide	Furosemide	32	15
Duloxetine Hcl	Duloxetine Hcl	31	13
Humulin N	Insulin Nph Human Isophane	31	13
Pantoprazole Sodium	Pantoprazole Sodium	31	13
Breyna	Budesonide/Formoterol Fumarate	29	17
Fluticasone Propionate	Fluticasone Propionate	27	11
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	26	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	26	suppressed
Hydrocortisone	Hydrocortisone	23	13
Azelastine Hcl	Azelastine Hcl	22	suppressed
Tradjenta	Linagliptin	22	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Digoxin	Digoxin	21	suppressed
Ibuprofen	Ibuprofen	21	14
Bisoprolol Fumarate	Bisoprolol Fumarate	20	suppressed
Lactulose	Lactulose	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Lovastatin	Lovastatin	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Citalopram Hbr	Citalopram Hydrobromide	17	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Alvesco	Ciclesonide	16	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Eliquis	Apixaban	16	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	16	suppressed
Sitagliptin	Sitagliptin	16	11
Betamethasone Valerate	Betamethasone Valerate	15	suppressed
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	14	14
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Ciclopirox	Ciclopirox	13	suppressed
Prednisone	Prednisone	13	suppressed
Baclofen	Baclofen	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Cartia Xt	Diltiazem Hcl	11	suppressed
Estradiol	Estradiol	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error